218 related articles for article (PubMed ID: 36445479)
1. Cystic kidney disease in tuberous sclerosis complex: current knowledge and unresolved questions.
Gallo-Bernal S; Kilcoyne A; Gee MS; Paul E
Pediatr Nephrol; 2023 Oct; 38(10):3253-3264. PubMed ID: 36445479
[TBL] [Abstract][Full Text] [Related]
2. Imaging features of tuberous sclerosis complex with autosomal-dominant polycystic kidney disease: a contiguous gene syndrome.
Back SJ; Andronikou S; Kilborn T; Kaplan BS; Darge K
Pediatr Radiol; 2015 Mar; 45(3):386-95. PubMed ID: 25355409
[TBL] [Abstract][Full Text] [Related]
3. Tuberous sclerosis complex: Hamartin and tuberin expression in renal cysts and its discordant expression in renal neoplasms.
Bonsib SM; Boils C; Gokden N; Grignon D; Gu X; Higgins JP; Leroy X; McKenney JK; Nasr SH; Phillips C; Sangoi AR; Wilson J; Zhang PL
Pathol Res Pract; 2016 Nov; 212(11):972-979. PubMed ID: 27640314
[TBL] [Abstract][Full Text] [Related]
4. Tuberous sclerosis and the kidney: from mesenchyme to epithelium, and beyond.
Henske EP
Pediatr Nephrol; 2005 Jul; 20(7):854-7. PubMed ID: 15856327
[TBL] [Abstract][Full Text] [Related]
5. Renal disease in tuberous sclerosis complex: pathogenesis and therapy.
Lam HC; Siroky BJ; Henske EP
Nat Rev Nephrol; 2018 Nov; 14(11):704-716. PubMed ID: 30232410
[TBL] [Abstract][Full Text] [Related]
6. Reprint of: lessons from histopathologic examination of nephrectomy specimens in patients with tuberous sclerosis complex: cysts, angiomyolipomas & renal cell carcinoma.
Gupta S; Stanton ML; Reynolds JP; Whaley RD; Herrera-Hernandez L; Jimenez RE; Cheville JC
Hum Pathol; 2023 Mar; 133():136-152. PubMed ID: 36894367
[TBL] [Abstract][Full Text] [Related]
7. Not all kidney cysts are created equal: a distinct renal cystogenic mechanism in tuberous sclerosis complex (TSC).
Soleimani M
Front Physiol; 2023; 14():1289388. PubMed ID: 38028758
[TBL] [Abstract][Full Text] [Related]
8. Tuberous sclerosis complex.
Islam MP; Roach ES
Handb Clin Neurol; 2015; 132():97-109. PubMed ID: 26564073
[TBL] [Abstract][Full Text] [Related]
9. Renal Neoplasia in Polycystic Kidney Disease: An Assessment of Tuberous Sclerosis Complex-associated Renal Neoplasia and PKD1/TSC2 Contiguous Gene Deletion Syndrome.
Gupta S; Lohse CM; Rowsey R; McCarthy MR; Shen W; Herrera-Hernandez L; Boorjian SA; Houston Thompson R; Jimenez RE; Leibovich BC; Cheville JC
Eur Urol; 2022 Mar; 81(3):229-233. PubMed ID: 34876325
[TBL] [Abstract][Full Text] [Related]
10. Lessons from histopathologic examination of nephrectomy specimens in patients with tuberous sclerosis complex: cysts, angiomyolipomas, and renal cell carcinoma.
Gupta S; Stanton ML; Reynolds JP; Whaley RD; Herrera-Hernandez L; Jimenez RE; Cheville JC
Hum Pathol; 2022 Nov; 129():123-139. PubMed ID: 36115585
[TBL] [Abstract][Full Text] [Related]
11. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling.
Tee AR; Fingar DC; Manning BD; Kwiatkowski DJ; Cantley LC; Blenis J
Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13571-6. PubMed ID: 12271141
[TBL] [Abstract][Full Text] [Related]
12. Treatment of renal angiomyolipoma in tuberous sclerosis complex (TSC) patients.
Brakemeier S; Bachmann F; Budde K
Pediatr Nephrol; 2017 Jul; 32(7):1137-1144. PubMed ID: 27585680
[TBL] [Abstract][Full Text] [Related]
13. Tuberin and hamartin are aberrantly expressed and linked to clinical outcome in human breast cancer: the role of promoter methylation of TSC genes.
Jiang WG; Sampson J; Martin TA; Lee-Jones L; Watkins G; Douglas-Jones A; Mokbel K; Mansel RE
Eur J Cancer; 2005 Jul; 41(11):1628-36. PubMed ID: 15951164
[TBL] [Abstract][Full Text] [Related]
14. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.
Chan JA; Zhang H; Roberts PS; Jozwiak S; Wieslawa G; Lewin-Kowalik J; Kotulska K; Kwiatkowski DJ
J Neuropathol Exp Neurol; 2004 Dec; 63(12):1236-42. PubMed ID: 15624760
[TBL] [Abstract][Full Text] [Related]
15. mTORC1 enhancement of STIM1-mediated store-operated Ca2+ entry constrains tuberous sclerosis complex-related tumor development.
Peng H; Liu J; Sun Q; Chen R; Wang Y; Duan J; Li C; Li B; Jing Y; Chen X; Mao Q; Xu KF; Walker CL; Li J; Wang J; Zhang H
Oncogene; 2013 Sep; 32(39):4702-11. PubMed ID: 23108404
[TBL] [Abstract][Full Text] [Related]
16. Mourning Dr. Alfred G. Knudson: the two-hit hypothesis, tumor suppressor genes, and the tuberous sclerosis complex.
Hino O; Kobayashi T
Cancer Sci; 2017 Jan; 108(1):5-11. PubMed ID: 27862655
[TBL] [Abstract][Full Text] [Related]
17. Tuberous sclerosis complex-associated angiomyolipomas: focus on mTOR inhibition.
Budde K; Gaedeke J
Am J Kidney Dis; 2012 Feb; 59(2):276-83. PubMed ID: 22130643
[TBL] [Abstract][Full Text] [Related]
18. [Tuberous sclerosis complex: A review].
Pfirmann P; Combe C; Rigothier C
Rev Med Interne; 2021 Oct; 42(10):714-721. PubMed ID: 33836894
[TBL] [Abstract][Full Text] [Related]
19. Renal cystic disease in tuberous sclerosis: role of the polycystic kidney disease 1 gene.
Sampson JR; Maheshwar MM; Aspinwall R; Thompson P; Cheadle JP; Ravine D; Roy S; Haan E; Bernstein J; Harris PC
Am J Hum Genet; 1997 Oct; 61(4):843-51. PubMed ID: 9382094
[TBL] [Abstract][Full Text] [Related]
20. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb.
Tee AR; Manning BD; Roux PP; Cantley LC; Blenis J
Curr Biol; 2003 Aug; 13(15):1259-68. PubMed ID: 12906785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
